AMC & GM to Part-MED — Amendment 1

European Aviation Safety Agency

Acceptable Means of Compliance and Guidance Material to Part-MED

Amendment 1 8 August 2013

AMC TO PART-MED AMENDMENT 1 – CHANGE INFORMATION

The text of the amendment is arranged to show deleted, new or amended text as shown below:

1. deleted text is marked with strike through;

2. new or amended text is highlighted in grey; and

3. an ellipsis (…) indicates that the remaining text is unchanged in front of or following the reflected amendment. Amendments Create a new AMC17 MED.B.095 and a new AMC18 MED.B.095 directly after existing AMC16 MED.B.095 as follows at: - AMC to Part-MED - Subpart B Specific Requirements for class 1, class 2 and LAPL medical certificates - AMC for class 1, class 2 and LAPL medical certificates - Section 4 Specific requirements for LAPL medical certificates AMC17 MED.B.095 Dermatology In cases where a dermatological condition is associated with a systemic disease, full consideration should be given to the underlying illness before a fit assessment may be considered. AMC18 MED.B.095 Oncology (a) In the case of malignant disease, applicants may be considered for a fit assessment if: (1) there is no evidence of residual malignant disease likely to jeopardise flight safety; (2) time appropriate to the type of tumour has elapsed since the end of primary treatment; (3) the risk of in-flight incapacitation from a recurrence or metastasis is sufficiently low; (4) there is no evidence of short or long-term sequelae from treatment that may adversely affect flight safety. (b) Arrangements for an oncological follow-up should be made for an appropriate period of time. …